This is a phase 2 randomized, double-blind controlled study to test the effect of omecamtiv mecarbil on progressive doses in patients with dyspnoea and ventricular dysfunction who were admitted for acute exacerbation of heart failure. The primary endpoint of the study was to evaluate the response in dyspnea after a 48-h infusion of omecamtiv mecarbil…

The benefits of regular physical activity are well established, but there are some controversies related to the potential harmful physical activity of high competition. To answer this question, the long-term development of elite athletes would be important. This point is poorly addressed in the literature and very little in relation to specific causes of death.…

This double-blind, multicenter randomized study compared aliskiren versus placebo in 613 patients with coronary artery disease and systolic blood pressure between 125 and 139 mm Hg (pre hypertensive stage) together with 2 risk factors. All patients underwent coronary intravascular ultrasonography (IVUS) and randomized to aliskiren 300 mg (305 patients) or placebo (308 patients). At 72…

Resynchronization therapy has shown benefits reducing morbidity and mortality in patients with heart failure and wide QRS. Many heart failure patients have mechanical dyssynchrony and this could be improved by resynchronization. The use of resynchronization “off label” in observational studies and small randomized studies raised up the need for a larger work to vouch this…